Palisade Bio, Inc. (NASDAQ:PALI – Get Free Report) Director Robert Baltera acquired 50,000 shares of the company’s stock in a transaction on Tuesday, November 17th. The stock was acquired at an average price of $1.01 per share, for a total transaction of $50,500.00. Following the purchase, the director directly owned 511,904 shares of the company’s stock, valued at approximately $517,023.04. This trade represents a 10.82% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Palisade Bio Stock Down 9.2%
PALI opened at $0.84 on Friday. Palisade Bio, Inc. has a 12-month low of $0.84 and a 12-month high of $2.85. The business has a 50 day moving average of $1.37 and a 200-day moving average of $1.80. The stock has a market cap of $150.58 million, a price-to-earnings ratio of -1.75 and a beta of 1.61.
Palisade Bio (NASDAQ:PALI – Get Free Report) last posted its earnings results on Tuesday, November 10th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). As a group, analysts expect that Palisade Bio, Inc. will post -0.24 earnings per share for the current year.
Institutional Trading of Palisade Bio
Several hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. grew its holdings in Palisade Bio by 65.1% in the 3rd quarter. American Century Companies Inc. now owns 205,883 shares of the company’s stock valued at $278,000 after buying an additional 81,192 shares in the last quarter. Soleus Capital Management L.P. increased its position in Palisade Bio by 14.8% during the 3rd quarter. Soleus Capital Management L.P. now owns 14,996,154 shares of the company’s stock worth $20,245,000 after buying an additional 1,932,467 shares during the period. Creek Drive Management Group LLC lifted its holdings in shares of Palisade Bio by 54.5% during the third quarter. Creek Drive Management Group LLC now owns 680,000 shares of the company’s stock worth $918,000 after buying an additional 240,000 shares in the last quarter. ACT Capital Partners L.P. acquired a new stake in shares of Palisade Bio during the third quarter worth $415,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Palisade Bio by 19.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 81,000 shares of the company’s stock worth $117,000 after buying an additional 13,110 shares in the last quarter. 11.79% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several research firms have commented on PALI. HC Wainwright decreased their price objective on shares of Palisade Bio to $5.00 and set a “buy” rating on the stock in a report on Wednesday, November 11th. Wall Street Zen cut shares of Palisade Bio from a “sell” rating to a “strong sell” rating in a research note on Saturday, November 14th. Raymond James Financial assumed coverage on shares of Palisade Bio in a report on Thursday, October 8th. They set an “outperform” rating and a $6.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a research note on Monday, October 12th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Palisade Bio in a research note on Wednesday, October 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $9.00.
Read Our Latest Stock Analysis on Palisade Bio
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, with a focus on oral treatments for inflammatory bowel conditions. Its pipeline includes PALI-2108, an investigational, gut-targeted PDE4 inhibitor being developed for ulcerative colitis and fibrostenotic Crohn’s disease. The company has also developed LB1148, an investigational serine protease inhibitor studied for its potential to support bowel function and reduce complications after abdominal surgery.
Further Reading
- Five stocks we like better than Palisade Bio
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
